CD4 and cancer: An effective CD4+ Th1 response, or INF-γ alone combined with oncogene blockade can significantly drive tumor senescence and apoptosis and should be explored as a non-cross-reactive therapy to effectively eliminate residual cancer cells and prevent recurrence in HER2-expressing and triple negative breast cancer.